Boston Scientific (BSX) Stock: Charts & Financials

Boston Scientific Corporation (BSX)BSXBoston Scientific Corporation

About Boston Scientific Corporation

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Marlborough, MA

59,000 employees

www.bostonscientific.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Michael F. Mahoney

View full financials

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Total Current Assets	N/A	N/A	8.68B	8.79B	8.04B	7.12B	7.33B	6.92B	8.76B
Cash & Cash Equivalents	N/A	N/A	1.52B	2.04B	1.27B	534.00M	725.00M	414.00M	2.50B
Short-Term Investments	N/A	N/A	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash & Short-Term Investments	N/A	N/A	1.52B	2.04B	1.27B	534.00M	725.00M	414.00M	2.50B
Accounts Receivable	N/A	N/A	3.03B	2.93B	2.83B	2.81B	2.69B	2.56B	2.50B
Inventory	N/A	N/A	3.12B	2.94B	2.92B	2.86B	2.87B	2.81B	2.75B
Total Assets	N/A	N/A	44.35B	43.67B	42.71B	41.56B	40.14B	39.40B	38.08B
Property, Plant & Equipment	N/A	N/A	4.61B	4.50B	4.29B	3.95B	3.84B	3.74B	3.50B
Goodwill	N/A	N/A	18.54B	18.28B	18.21B	18.08B	17.34B	17.09B	15.03B
Intangible Assets	N/A	N/A	7.06B	7.02B	7.16B	7.26B	6.57B	6.68B	5.75B
Long-Term Investments	N/A	N/A	935.00M	842.00M	792.00M	626.00M	655.00M	555.00M	532.00M
Total Current Liabilities	N/A	N/A	4.57B	5.44B	5.33B	5.19B	5.06B	6.40B	5.91B
Accounts Payable	N/A	N/A	1.14B	1.14B	1.00B	962.00M	1.00B	960.00M	907.00M
Short-Term Debt	N/A	N/A	41.00M	389.00M	483.00M	480.00M	777.00M	1.78B	1.65B
Total Liabilities	N/A	N/A	18.25B	19.20B	19.08B	18.91B	17.69B	17.39B	17.12B
Long-Term Debt	N/A	N/A	10.86B	11.46B	10.99B	10.98B	10.41B	8.84B	9.23B
Total Debt	N/A	N/A	11.03B	12.42B	12.05B	12.03B	11.71B	11.15B	11.26B
Net Debt (Cash)	N/A	N/A	9.51B	10.37B	10.77B	11.49B	10.98B	10.73B	8.76B
Total Shareholders' Equity	N/A	N/A	25.86B	24.23B	23.39B	22.42B	22.21B	21.77B	20.71B
Common Stock	N/A	N/A	17.00M	17.00M	17.00M	17.00M	17.00M	17.00M	17.00M
Retained Earnings	N/A	N/A	6.91B	5.57B	4.90B	4.14B	3.35B	2.67B	2.11B
Current Ratio	N/A	N/A	1.90	1.62	1.51	1.37	1.45	1.08	1.48
Debt to Equity Ratio	N/A	N/A	0.43	0.51	0.51	0.54	0.53	0.51	0.54

Quarterly Report

TTM

Quarter ended Jun 2026

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Total Current Assets

N/A

8.68B

8.79B

8.04B

7.12B

7.33B

6.92B

8.76B

Cash & Cash Equivalents

N/A

1.52B

2.04B

1.27B

534.00M

725.00M

414.00M

2.50B

Short-Term Investments

N/A

0.00

Cash & Short-Term Investments

N/A

1.52B

2.04B

1.27B

534.00M

725.00M

414.00M

2.50B

Accounts Receivable

N/A

3.03B

2.93B

2.83B

2.81B

2.69B

2.56B

2.50B

Inventory

N/A

3.12B

2.94B

2.92B

2.86B

2.87B

2.81B

2.75B

Total Assets

N/A

44.35B

43.67B

42.71B

41.56B

40.14B

39.40B

38.08B

Property, Plant & Equipment

N/A

4.61B

4.50B

4.29B

3.95B

3.84B

3.74B

3.50B

Goodwill

N/A

18.54B

18.28B

18.21B

18.08B

17.34B

17.09B

15.03B

Intangible Assets

N/A

7.06B

7.02B

7.16B

7.26B

6.57B

6.68B

5.75B

Long-Term Investments

N/A

935.00M

842.00M

792.00M

626.00M

655.00M

555.00M

532.00M

Total Current Liabilities

N/A

4.57B

5.44B

5.33B

5.19B

5.06B

6.40B

5.91B

Accounts Payable

N/A

1.14B

1.00B

962.00M

1.00B

960.00M

907.00M

Short-Term Debt

N/A

41.00M

389.00M

483.00M

480.00M

777.00M

1.78B

1.65B

Total Liabilities

N/A

18.25B

19.20B

19.08B

18.91B

17.69B

17.39B

17.12B

Long-Term Debt

N/A

10.86B

11.46B

10.99B

10.98B

10.41B

8.84B

9.23B

Total Debt

N/A

11.03B

12.42B

12.05B

12.03B

11.71B

11.15B

11.26B

Net Debt (Cash)

N/A

9.51B

10.37B

10.77B

11.49B

10.98B

10.73B

8.76B

Total Shareholders' Equity

N/A

25.86B

24.23B

23.39B

22.42B

22.21B

21.77B

20.71B

Common Stock

N/A

17.00M

Retained Earnings

N/A

6.91B

5.57B

4.90B

4.14B

3.35B

2.67B

2.11B

Current Ratio

N/A

1.90

1.62

1.51

1.37

1.45

1.08

1.48

Debt to Equity Ratio

N/A

0.43

0.51

0.54

0.53

0.51

0.54

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Total Current Assets	8.79B	6.92B	6.51B	5.76B	6.32B	6.69B	4.70B	4.00B
Cash & Cash Equivalents	2.04B	414.00M	865.00M	928.00M	1.93B	1.73B	217.00M	146.00M
Short-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash & Short-Term Investments	2.04B	414.00M	865.00M	928.00M	1.93B	1.73B	217.00M	146.00M
Accounts Receivable	2.93B	2.56B	2.23B	1.97B	1.78B	1.53B	1.83B	1.61B
Inventory	2.94B	2.81B	2.48B	1.87B	1.61B	1.35B	1.58B	1.17B
Total Assets	43.67B	39.40B	35.14B	32.47B	32.23B	30.78B	30.57B	21.00B
Property, Plant & Equipment	4.50B	3.74B	3.30B	2.83B	2.69B	2.54B	2.42B	1.78B
Goodwill	18.28B	17.09B	14.39B	12.92B	11.99B	9.95B	10.18B	7.91B
Intangible Assets	7.02B	6.68B	6.00B	5.90B	6.12B	5.92B	7.89B	6.37B
Long-Term Investments	842.00M	555.00M	413.00M	407.00M	412.00M	918.00M	458.00M	-328.00M
Total Current Liabilities	5.44B	6.40B	4.93B	3.80B	4.27B	3.68B	4.87B	5.26B
Accounts Payable	1.14B	960.00M	942.00M	862.00M	794.00M	513.00M	542.00M	349.00M
Short-Term Debt	389.00M	1.78B	531.00M	20.00M	261.00M	13.00M	1.42B	2.25B
Total Liabilities	19.20B	17.39B	15.61B	14.90B	15.61B	15.45B	16.69B	12.27B
Long-Term Debt	11.46B	8.84B	8.57B	8.91B	8.80B	9.12B	8.59B	4.80B
Total Debt	12.42B	11.15B	9.49B	9.28B	9.45B	9.54B	10.28B	7.03B
Net Debt (Cash)	10.37B	10.73B	8.63B	8.35B	7.53B	7.80B	10.06B	6.88B
Total Shareholders' Equity	24.23B	21.77B	19.28B	17.57B	16.62B	15.33B	13.88B	8.72B
Common Stock	17.00M	17.00M	17.00M	17.00M	17.00M	17.00M	16.00M	16.00M
Retained Earnings	5.57B	2.67B	819.00M	-750.00M	-1.39B	-2.38B	-2.25B	-6.95B
Current Ratio	1.62	1.08	1.32	1.51	1.48	1.82	0.97	0.76
Debt to Equity Ratio	0.51	0.51	0.49	0.53	0.57	0.62	0.74	0.81

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Total Current Assets

8.79B

6.92B

6.51B

5.76B

6.32B

6.69B

4.70B

4.00B

Cash & Cash Equivalents

2.04B

414.00M

865.00M

928.00M

1.93B

1.73B

217.00M

146.00M

Short-Term Investments

0.00

Cash & Short-Term Investments

2.04B

414.00M

865.00M

928.00M

1.93B

1.73B

217.00M

146.00M

Accounts Receivable

2.93B

2.56B

2.23B

1.97B

1.78B

1.53B

1.83B

1.61B

Inventory

2.94B

2.81B

2.48B

1.87B

1.61B

1.35B

1.58B

1.17B

Total Assets

43.67B

39.40B

35.14B

32.47B

32.23B

30.78B

30.57B

21.00B

Property, Plant & Equipment

4.50B

3.74B

3.30B

2.83B

2.69B

2.54B

2.42B

1.78B

Goodwill

18.28B

17.09B

14.39B

12.92B

11.99B

9.95B

10.18B

7.91B

Intangible Assets

7.02B

6.68B

6.00B

5.90B

6.12B

5.92B

7.89B

6.37B

Long-Term Investments

842.00M

555.00M

413.00M

407.00M

412.00M

918.00M

458.00M

-328.00M

Total Current Liabilities

5.44B

6.40B

4.93B

3.80B

4.27B

3.68B

4.87B

5.26B

Accounts Payable

1.14B

960.00M

942.00M

862.00M

794.00M

513.00M

542.00M

349.00M

Short-Term Debt

389.00M

1.78B

531.00M

20.00M

261.00M

13.00M

1.42B

2.25B

Total Liabilities

19.20B

17.39B

15.61B

14.90B

15.61B

15.45B

16.69B

12.27B

Long-Term Debt

11.46B

8.84B

8.57B

8.91B

8.80B

9.12B

8.59B

4.80B

Total Debt

12.42B

11.15B

9.49B

9.28B

9.45B

9.54B

10.28B

7.03B

Net Debt (Cash)

10.37B

10.73B

8.63B

8.35B

7.53B

7.80B

10.06B

6.88B

Total Shareholders' Equity

24.23B

21.77B

19.28B

17.57B

16.62B

15.33B

13.88B

8.72B

Common Stock

17.00M

16.00M

Retained Earnings

5.57B

2.67B

819.00M

-750.00M

-1.39B

-2.38B

-2.25B

-6.95B

Current Ratio

1.62

1.08

1.32

1.51

1.48

1.82

0.97

0.76

Debt to Equity Ratio

0.51

0.49

0.53

0.57

0.62

0.74

0.81

Balance Sheet

Quarterly Balance Sheet (USD)

Annual Balance Sheet (USD)